Silver Colloidal Nanoparticle, a Safe Natural Alternative Immunity Booster for Combating Pathogens Including SARS-CoV2: An Overview

Jump To References Section

Authors

  • Gopal Dutta (Rajdeep)
  • Sukhen Roy
  • Chandan Dutta
  • Amartya Neogi
     Dr. B. C. Roy Engineering College, Durgapur ,IN

DOI:

https://doi.org/10.24906/isc/2020/v34/i3/203787

Keywords:

Silver, Nanoparticles, Colloidal, SARS-CoV2, Antiviral Agent, Pathogens, Antibiotic Resistance, Immunity Booster, Natural Healer, Microbes.

Abstract

Antibiotic resistant microbes are now considered epidemic in whole world. Most of the antibiotic disinfect about half a dozen microbes while the silver nanoparticles in the form of colloidal silver fights against almost all microorganisms and produce a constraint for multiplication. Most importantly while conventional antibiotic cannot build as much as opposing to the action of microbes as compared to silver. Pure colloidal silver when prepared appropriately is a special preparation of trace minerals. It is much safe for the usage and also makes a significant resistance on the said microorganism. In this review study, there is an effort to prove elaborately of silver nanoparticles on the effect of human body, where appropriately prepared colloidal silver is fully non-toxic, noncarcinogenic, internally and externally applicable to fight broad-spectrum germs. It is disinfectant that works on human bodies. Silver nanoparticles in colloidal formare more effective against various pathogens. Nowadays, SARS-CoV2 is responsible for pandemic COVID-19 all over the world. We hypothesize colloidal silver as a significantly effective, natural safe alternative of recent days against SARS-CoV2. It was found the relation between low silver level and illness in human body. Those people having low silver level have high chance to fall sick with cold, flu, fever and other illness. Silver also boost up immune system of our body. It assists fibroblast cell to repair the injured tissues.

Downloads

Download data is not yet available.

Downloads

Published

2020-05-01

How to Cite

(Rajdeep), G. D., Roy, S., Dutta, C., & Neogi, A. (2020). Silver Colloidal Nanoparticle, a Safe Natural Alternative Immunity Booster for Combating Pathogens Including SARS-CoV2: An Overview. Indian Science Cruiser, 34(3), 38–49. https://doi.org/10.24906/isc/2020/v34/i3/203787

Issue

Volume 34, Issue 3, May 2020

Section

Search & Survey
Crossref
Scopus
Google Scholar
Europe PMC

 

References

Mahamati Shreemad Bag Bhattacharya, “Rasaratna Samuchhayaâ€

H Assar Nauran, M Hamuoda Hayam, Coolloidal Silver as a New Antimicrobial Agent., (2010). International Journal of Microbial Research 1 (1) : pp. 33-36,2010.

E O Miner, and C N Eatough (25 Dec. 2007). Antiseptic solutions containing silver chelated with polypectate and EDTA, U.S. Patent No. 7,311,927. U.S. Patent No. 7,311,927.

A R Harvey, (8 Oct. 2013). Ceramic water purification device. U.S. Patent No. 8,550,257.

J A King, (09 Dec. 2013). Drinking water purification device. US 12,803,966.

T Pradeep et al. (24 Jul. 2014). Sustained silver release composition for water purification. U.S. Patent No. 20,140,202,943

D Tessier, et al. (8 Oct. 2009). New antimicrobial material. U.S. Patent No. 20,090,252,861.

J Glenn, et al. (16 Aug. 2007). Antimicrobial reusable plastic container. U.S. Patent No. 20,070,189,932.

J Schiffmann, and H Schlösser (29 Mar. 2011). Antimicrobial food packaging. U.S. Patent No. 7,915,325.

G-N Bae, et al. (8 May 2012). Multi-functional cabin air filter. U.S. Patent No. 8,172,925.

E-P Kim, and K-S Kim (16 Aug. 2005). Combination air purifier and wind generator. U.S. Patent No. 6,929,671.

R H Ma, and Y H Yu (9 Dec. 2008). Nano-silver wound dressing. USPTO, US 11,455,188.

Y S Lee, (21 Feb. 2011). Clothes washing machine, US 10,582,160.

B W Whitchurch, et al. (22 Oct. 2009). Submersible keyboard. U.S. Patent No. 20,090,262,492.

H-K Kim, (24 Aug. 2010). Antibiotic method for parts of refrigerator using antibiotic substance. U.S. Patent No. 7,781,497.

Y Nabutovsky, et al. (11 Feb. 2014). Silver nanoparticle antimicrobial coating for long-term and short-term infection resistance. U.S. Patent No. 8,647,675.

A T Hunt, et al. (28 Jan. 2010). Antimicrobial coatings. U.S. Patent No. 20,100,021,710.

V V Kopeikin and E F Panarin. 2001. Water-Soluble Nanocomposites of Zerovalent Metallic Silver with Enhanced Antimicrobial Activity. Doklady Chemistry. 380:277.

H Bönnemann, and R M. Richards. Nanoscopic Metal Particles, Synthetic Methods and Potential Applications. Eur. J Inorg. Chem. 2455, 2001.

M V Canamares, Garcia-Rames, S Sanchez-Cortes, M Castillejo and M Oujja. Cooperative SERS effectiveness of silver nanoparticles prepared by different methods; a study of the enhancement factor and the interfacial properties , J. Colloid interface. Sci.326:103-109, doi:10.1016/j.jcis.2008.06.052, 2008.

M E Samberg, P E Orndorff, and N A MouteiroRiviere., Antibacterial efficacy of silver nanoparticles of different sizes , surface conditions and synthesis methods , Nanotoxicology, doi:10.3109.17435390.20 10.525669, 2010.

M K Hossain, Y Kitahama, J J Huang, X Han,Y Ozaki, Surface enhanced raman scattering : realization of localized plasmon resonance using unique subtrates and methods .Anal Bioanal Chem.394;pp. 1747-1760. Doi:10.1007/s00216-0092762-4, 2009.

S Gaikwad, A Ingle, A Gade, et al., Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3. Int J Nanomed 8: pp. 4303–14, 2013.

D Ganem, AM Prince, Hepatitis B virus infection natural history and clinical consequences. N Engl J Med; 350:pp.1118-1129, 2004.

GKK Lau, T Piratvisuth, KX Luo et al. Peginterferon alfa-2a , lamivudine and the combination for H Be Ag-positive chronic hepatitis B. N Engl J Med: 352: pp.2682:2695, 2005.

L Lu, RW Sun, R Chen et al., 2008. Silver nanoparticles inhibit hepattis B virus replication, Antivirus Ther 13: pp.253-62, 2008..

W Brian, J Mahy and Marc H V Van Regenmortel(Editor-in-Chief), Encyclopedia of virology(3rd edition). books.elsevier.com, 2008.

DX Xiang, Chen Q, Pang L, Zheng CL, Inhibitory effect of silver nanoparticles on H1N1 influenza A virus invitro J viral method, 2011.

P Mehrbod, MotamedN ,Tobatabaian M et al.,2009. In- vitro antiviral effects of “nanosilver†on influenza virus. DARU 17:pp. 88-93, 2009.

R Mahendra, D Deshmukh Shivaji, et al., 2014. Metal nanoparticles :The protective nanoshield against virus infection. DOI: 10.3109/1040841X.2013.879849.

DA Tyrrell, ML Bynoe. Cultivation of viruses from a high proportion of patients with colds. Lancet.;1:pp.76–77, 1966.

F Amanat, F Krammer (2020). SARS-CoV2-vaccines:status report. Immunity, 52(4),583-589. https://doi.org/10.1016/j.immuni.2020.03.007

C Drosten, S Gunther, W Preiser, S van der Werf, H R Brodt, S Becker, H Rabenau, M Panning, L Kolesnikova, R A Fouchier, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, pp.1967–1976, 2003.

T G Ksiazek, D Erdman, C S Goldsmith, S R Zaki, T Peret, S Emery, S Tong, C Urbani, J A Comer, W Lim et al.; SARS Working Group A novel coronavirus associated with severe acute respiratory syndrome.N. Engl. J. Med. 348, pp.1953–1966, 2003.

A M Zaki, S van Boheemen, T M Bestebroer, A D Osterhaus, and R A Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, pp.1814–1820, 2012.

C Huang, Y Wang, X Li, L Ren, J Zhao, Y Hu, L Zhang, G Fan, J Xu, X Gu, et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan (China: Lancet).

P Zhou, X L Yang, XG Wang, B Hu, L Zhang, W Zhang, H R Si, Y Zhu, B Li, C L Huang, et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. Published online February 3, 2020. https://doi.org/10.1038/s41586-020-2012-7.

N Zhu, D Zhang, W Wang, X Li, B Yang, J Song, X Zhao, B Huang, W Shi, R Lu, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 382, 7, pp. 27–733, 2020.

X Y Ge, J L Li, X L Yang, A A Chmura, G Zhu, J H Epstein, J K Mazet, B Hu, W Zhang, C Peng, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, pp.535–538, 2013.

B Hu, L P Zeng, X L Yang, X Y Ge, W Zhang, B Li, J Z Xie, X R Shen, Y Z Zhang, N Wang, et al. Discovery of a rich gene pool of bat SAR Srelated coronaviruses provides new insights into the origin of SARS coronavirus. PLoSPathog. 13, e1006698, 2017.

W Li, Z Shi, M Yu, W Ren, C Smith, J H Epstein, H Wang, G Crameri, Z Hu, H Zhang, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310, pp.676–679, (2005b).

X L Yang, B Hu, B Wang, M N Wang, Q Zhang, W Zhang, L J Wu, X Y Ge, Y Z Zhang, P Daszak, et al., Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus. J. Virol. 90, pp. 3253–3256, 2015a.

S J Anthony, K Gilardi, V D Menachery, T Goldstein, B Ssebide, R Mbabazi, I NavarreteMacias, E Liang, H Wells, A Hicks, et al. (2017). Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. MBio 8, e00373-17.

V D Menachery, B L Jr. Yount, K Debbink, S Agnihothram, L E Gralinski, J A Plante, R L Graham, T Scobey, X Y Ge, E F Donaldson, et al. (2015). A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, pp.1508–1513, 2015.

V D Menachery, B L Jr. Yount, A C Sims, K Debbink, S S Agnihothram, L E Gralinski, R L Graham, T Scobey, J A Plante, S R Royal et al. (2016). SARSlike WIV1-CoV poised for human emergence. Proc. Natl. Acad. Sci. USA 113, pp.3048–3053, 2016.

International committee of virus taxonomy: 2018, “Virus Taxonomy†https://talk.ictvonline.org/taxonomy/p/taxonomy_releases

W Li, C Zhang, J Sui, J H Kuhn, M J Moore, S Luo, S K Wong, I C Huang, K Xu, N Vasilieva, et al., Receptor and viral determinants of SARScoronavirus adaptation to human ACE2. EMBO J. 24, pp.1634–1643, 2005c.

F Li, Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J. Virol. 82, pp. 6984–6991, 2008.

W Li, T C Greenough, M J Moore, N Vasilieva, M Somasundaran, J L Sullivan, M Farzan, and H Choe, Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin converting enzyme 2. J. Virol. 78, pp.11429–11433, 2004.

C Walls Alexandra, Park Young-Jun, Tortorici M Alejandra, Wall Abigail, T McGuire, Veesler David.,(2020) Structure,Function and Antiginicityof the SARS-CoV2 Spike Glycoprotein, https://doi.org/10.1016/j.cell.2020.02.058

S Voyutsky, Colloid Chemistry, translated by N. Bobrov. Mir Publishers: Moscow, p.21., 1978.

Ibid., ( Quoting Henry Crookes) p. 70.

AF Holleman, E. Wiberg Lehrbuch der anorganischenChemie. [Textbook of inorganicchemistry.] Berlin, Walter de Gruyter, 1985.

LM Canty, Z Baranowski, Colloidal Silver, The Antibiotic Alternative, The Colloid Research Foundation, Carmighael, CA, 1994.

R. Becker “Colloidal Silver and illnessâ€.

WHO/SDE/WSH/03.04/14 Guidelines for drinkingwater quality, 2nd ed. Vol. 2. Health criteria andother supporting information. World Health Organization, Geneva, 1996.

AA Goldberg, M Shapiro, E. Wilder Antibacterial colloidal electrolytes: the potentiation of the activities of mercuric-, phenylmercuric- and silver ions by a colloidal sulphonic anion. Journal of pharmacy and pharmacology, 2: pp.20-26, 1950.

J Rungby, Danscher G Hypoactivity in silver exposed mice. Acta pharmacologica ettoxicologica, 1984, 55:pp. 398-401, 1984.

CT Olcott Experimental argyrosis. V Hypertrophy of the left ventricle of the heart. Archives of pathology, 49: pp.138-149, 1950.

CT. Olcott Experimental argyrosis. III. Pigmentation of the eyes of rats following ingestion of silver during long periods of time. American journal of pathology, 23:783, 1947.

PA Wagner, WG Hoekstra, Ganther HE. Alleviation of silver toxicity by selenite in the rat in relation to tissue glutathione peroxidase. Proceedings of the Society of ExperimentalBiology and Medicine, 1975, 148:pp. 106-1110, 1975.

H Nishioka Mutagenic activities of metal compounds in bacteria. Mutation research, 31:pp.185-189, 1975.

M Demerec, G Bertani, J Flint A survey of chemicals for mutagenic action on E. coli. The American naturalist, 85:pp. 119-136, 1951.

F Denizeau, M Marion Genotoxic effects of heavy metals in rat hepatocytes. Cell biologyand toxicology, 5:pp.15-25, 1989.

BC Casto, J Meyers, DiPaolo JA Enhancement of viral transformation for evaluation of the carcinogenic or mutagenic potential of inorganic salts. Cancer research, 39:193, 1979.

A Furst, MC Schlauder Inactivity of two noble metals as carcinogens. Journal ofenvironmental pathology and toxicology, 1977, 1:pp. 51-57, 1977.

WR Hill, DM. Pillsbury Argyria, the pharmacology of silver. Baltimore, MD, Williams and Wilkins, 1939 (cited in reference 5).

BW East et al. Silver retention, total body silver and tissue silver concentrations in argyria associated with exposure to an anti-smoking remedy containing silver acetate. Clinical andexperimental dermatology, 5:pp.305-311, 1980.

M Westhofen, H. Schäfer Generalized argyria in man: neurological, ultrastructural and X-ray microanalytic findings. Archives of otorhinolaryngology, 243: pp. 260-264, 1986.

LE Gaul, AH Staud Clinical spectroscopy. Seventy cases of generalized argyrosis following organic and colloidal silver medication. Journal of the American MedicalAssociation, 104:pp.1387-1390, 1935.

R A Kehoe, J Cholak and R V Story, A spectrochemical study of the normal ranges of concentration of certain trace metals in biological materials, Journal of Nutrition, 19:579, 1940.